Skip to main content

Table 4 Other questionnaires

From: Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patients

Parameter

Months

 

T0

T3

T6

T12

POMS Tension-Anxiety

60.14 ± 6.14

65.71 ± 5.42

53.14 ± 4.86

58.71 ± 4.32

POMS Depression-Dejection

63.42 ± 7.16

70.28 ± 6.75

58.14 ± 6.69

65.00 ± 6.88

POMS Anger-Hostility

66.00 ± 7.45

68.14 ± 7.35

60.14 ± 4.36

61.85 ± 4.83

POMS Vigor-Activity

44.14 ± 3.90

37.28 ± 3.34

44.00 ± 3.50

42.28 ± 5.42

POMS Fatigue-Inertia

66.85 ± 7.25

72.00 ± 6.20

64.14 ± 6.42

64.56 ± 6.11

POMS Confusion-Bewilderment

60.85 ± 7.64

68.28 ± 7.66

58.28 ± 5.81

61.14 ± 7.22

SF-36 Mental Index

39.42 ± 5.98

35.00 ± 3.65

45.57 ± 4.33

48.42 ± 3.73*

CES-D

21.14 ± 6.55

27.85 ± 5.09

25.14 ± 4.71

22.71 ± 5.25

  1. Scores of POMS, SF-36 and CESD questionnaires administered before (T0) and after 3 (T3), 6 (T6) and 12 (T12) months of testosterone replacement therapy. Values are mean ± SEM (n = 9). Wilcoxon test: * p < 0.04 vs T0